Stock Movers: Intel, Novo Nordisk, FedEx (Podcast)

Intel shares surged 23% following Nvidia's $5 billion investment and chip co-development agreement, marking the chipmaker's largest rally in nearly four decades and significantly increasing the value of the US government's recent stake. Meanwhile, Novo Nordisk rose sharply after its diabetes drug Ozempic showed superior cardiovascular benefits over Eli Lilly's Trulicity in a real-world study. FedEx also reinstated its full-year profit outlook, projecting FY2026 adjusted earnings of $17.20-$19.00 per share and revenue growth up to 6%, indicating improved business clarity despite persistent tariff pressures.

Analysis

Intel (INTC) experienced a significant re-rating event, with its shares surging 23% to $30.57, the largest rally in nearly four decades. This was catalyzed by a $5 billion strategic investment from industry peer Nvidia, which includes a partnership to co-develop chips for PCs and data centers. This move serves as powerful validation, following the US government's recent acquisition of a roughly 10% stake in Intel at $20.47 per share. The government's investment has already yielded a substantial paper gain of $4.4 billion, underscoring the market's positive reception to this new strategic direction. In the healthcare sector, Novo Nordisk (NVO) gained after its diabetes drug, Ozempic, demonstrated superior cardiovascular outcomes compared to Eli Lilly's (LLY) Trulicity in a real-world study of nearly 60,000 Medicare patients. The data showed Ozempic users had a 23% lower likelihood of heart attack, stroke, or death, reinforcing its competitive position and potential for market share gains. Meanwhile, FedEx (FDX) signaled improving business clarity by reinstating its fiscal year 2026 profit outlook. The company projects adjusted EPS of $17.20 to $19.00, with a midpoint slightly below the analyst consensus of $18.25, but forecasts strong revenue growth of up to 6%, significantly outpacing the 1.2% average analyst estimate, suggesting management confidence despite ongoing tariff pressures.

Key Decisions for Investors

• The dual validation for Intel from Nvidia's strategic investment and the US government's profitable stake suggests a material de-risking of its turnaround; investors should re-evaluate INTC's long-term competitive position in the data center and PC markets.
• Novo Nordisk's positive real-world data for Ozempic directly challenges Eli Lilly's Trulicity, indicating potential for market share shifts; positions in both NVO and LLY should be reviewed in light of this new clinical evidence.
• FedEx's reinstated guidance presents a nuanced picture; while the EPS forecast is cautious, the strong revenue growth outlook warrants attention, and investors should scrutinize the company's ability to manage margins and convert top-line strength into bottom-line profit.